media – Page 509 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Discovery of anti-stroke compound

A research team led by Yokohama City University and Toyama Chemical Co Ltd in Japan has developed a small compound named edonerpic maleate that showed enhanced recovery of motor function after brain damage in animal trials.
- Source: Ddu
- 590
- May 18, 2018
Clinical Trials Researches stroke
Apple health record app can disrupt the health data industry

iPhone maker Apple is all set to disrupt the conventionalities of medical data storage methodologies. The company has announced the development of a new health record app, a new standard that has been adopted by many big companies for transferring records across scattered systems. Apple is all set to break the traditional systems of several silos in which medical data is stored.
- Source: drugdu
- 747
- May 18, 2018
Company Insight digital health mHealth
Marico to focus on the healthcare startup

FMCG major Marico has announced that it will be investing in Revolutionary Fitness, owner of health and fitness app Revofit. The company stated that it will acquire around 22.5 percent stake in the health startup.
- Source: Ddu
- 671
- May 18, 2018
Company Insight health apps mHealth
EIP Pharma bags $20.5M to support Alzheimer’s drug through phase 2

EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
- Source: Ddu
- 574
- May 18, 2018
Alzheimer's disease Clinical Trials
R&D for organ-on-a-chip tech by AstraZeneca and Emulate.

AstraZeneca has collaborated with Emulate integrate an organ-on-a-chip technology into the R&D program of the pharma giant. It is meant to expedite the technology’s development within the company.
- Source: Ddu
- 767
- May 17, 2018
AstraZeneca Researches
AbbVie pressurized to keep low price for Imbruvica formula

This year AbbVie launched Imbruvica, a single tablet for blood cancer treatment. It has been designed as a convenient therapy measure for patients who used the old tablets as often as four times a day. Adapting the new single tablet in their treatment regimens will prove to be an expensive proposition for some patients as the new tablet comes with a price tag of $400 each, triple the cost of the older tablets.
- Source: Ddu
- 1,107
- May 17, 2018
AbbVie Company Insight pharma pharmaceutical
The imperative for securing connected medical devices

The implementation of privacy protocols and security controls is pertinent to protecting patient records and sensitive data. However, the threat to patient safety, the core of every modern health system, being compromised is growing rapidly owing to network-connected medical devices.
- Source: Ddu
- 679
- May 17, 2018
digital health Market Views medical device
Odour Orders Malarial Transmission

A simple key strategy discovered by the research team at the London School of Tropical Medicine, will turn out to be a major breakthrough in the field of Malarial prevention. Malaria-infected children were more prone to malarial mosquitoes by producing distinctive skin smells, compared to uninfected children.
- Source: Ddu
- 509
- May 17, 2018
malaria Researches
Breakdown of Pharma Events Since 2017

As a new, erratic administration consolidated its position in the White House and firmed its foundations in the federal government, 2017 turned out to be uncertain for the biopharma industry. Then President-elect Donald Trump saying that the industry was getting away with murder on pricing did not bode well for the industry but more than a year later after the President assuming office, real reform has been spared for biopharma.
- Source: Ddu
- 650
- May 17, 2018
global pharma influencers Market Views pharma
Trump calls for FDA price check with drug prices in ads

A particular proposal regarding displaying drug prices in TV ads flummoxed pharma marketers and ad agencies following the unveiling of the drug-pricing agenda by President Trump. Marketers have been hounded with the whys and hows of the proposal even as the administration remains firm on its implementation.
- Source: Ddu
- 808
- May 17, 2018
biopharmaceutical FDA pharma Policies

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.